AZZLY®, Inc, One of Six Women-founded Health Technology Companies Selected for Summer Scale-Up Accelerator Cohort
On July 10-11, 2019, AZZLY® Founder and CEO Coletta Dorado is representing AZZLY in GuideWell and Springboard's "Scale-Up" event for female-led tech companies. Behavioral healthcare technology company AZZLY®, Inc. was selected by GuideWell Innovation, in affiliation with Springboard Enterprises, as…
New Jersey Behavioral Health Providers Should Consider an All-in-One EHR
Last month, New Jersey legislators announced they were committing $6 million to support behavioral health providers in the implementation of electronic health records in their facilities and connection to other health care providers. This New Jersey Health Information Network (NJHIN)…
How The SUPPORT for Patients and Communities Act Helps Fix a 15-Year-Old Issue with Buprenorphine
Related: Senate Passes Opioid Crisis Response Act – Here's What's in It We wrote in the fall about the U.S. House of Representatives' SUPPORT for Patients and Communities Act, or H.R.6. H.R.6 would go on to become the Opioid Crisis…
Walmart Will Require All Locations to Have EPCS in 2020
Walmart announced recently that they will require all of their pharmacies (more than 4,000) to use e-prescribing of controlled substances when prescribing opioids, effective January 1, 2020. Put differently, any healthcare organization whose patients use a Walmart pharmacy must use…
Time for a New Behavioral Health EHR? Five Reasons to Consider It
Many in the behavioral health community have found themselves searching for a new EHR in 2019. Whether they're affected by the increased workload of the opioid epidemic and the Opioid Crisis Response Act, the concern of meeting HIPAA requirements due…
AZZLY Rize™ Prevents Death by a Thousand Clicks
Why We Dedicated Ourselves to Make a Better EHR In spring 2019, Fortune and Kaiser Health News joint-published a long-form investigative article titled "Death by a Thousand Clicks: Where Electronic Health Records Went Wrong." The 9,000-word critique on the medical…
FDA Approves Postpartum Depression Drug Zulresso, But Concerns Arise Over Cost
In mid-March, the FDA approved the postpartum depression drug brexanolone, providing an option to millions of women who suffer from postpartum depression. Brexanolone is the first federally-approved drug of its kind to be designed specifically to treat postpartum depression. The…
CDC Study: Opioid Overdose Deaths May Be in Decline
At a time when most news about the opioid crisis seems to be bad, a recent study may be a cause for hope. The January 2019 study by the Center for Disease Control (CDC) indicates that opioid overdose deaths in…
Three Reasons You Should Be Measuring Your Outcomes
In the digital era, it is crucial for behavioral health organizations to track their outcomes. Measuring outcomes holds facilities accountable and allows them to improve, benefiting clinicians and patients alike. Major accreditation agencies are recognizing the importance of outcome measurement…
